Please assess the completion status of the following clinical trial:

Trial Title: Low-Dose Tenecteplase in Covid-19 Diagnosed With Pulmonary Embolism

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or non-pregnant female adult ≥18 years of age, but \< 75 years of age at time of enrollment.~2. Laboratory-confirmed SARS-CoV-2 infection as determined by PCR, or other commercial or public health assay in any specimen \< 28 days prior to randomization, OR person under investigation (PUI) of COVID-19 with pulmonary infiltrates and elevated ferritin and CRP level.~3. Acute intermediate-risk pulmonary embolism defined as:~   * Presence of acute pulmonary embolism confirmed by diagnostic imaging (computed tomographic angiography, ventilation-perfusion scan, or invasive pulmonary angiography) AND~  * Presence of clot burden with at least one lobar artery involved OR bilateral with at least segmental branches OR unilateral clot in at least multiple segmental branches.~4. Subject (or legally authorized representative) provides written informed consent prior to the performance of any study procedures.~5. In the Investigator's judgement, patient has the ability to comply with the study protocol, and understands and agrees to comply with planned TNK bolus versus placebo.~Exclusion Criteria:~1. Anticipated transfer to another hospital (which is not a study site) within 72 hours~2. Allergy or contraindications to TNK~3. Contraindications to systemic anticoagulation~4. Active bleeding~5. Known significant bleeding risk (although recent exposure to aspirin or any other antiplatelet therapy is not an exclusion criterion). While there is no specific hemoglobin cut-off value for enrollment, Investigators will gauge the severity / stability of the Hgb and exclude patients deemed inappropriate.~6. Major GI or GU bleed within the past 3 weeks~7. History of hemorrhagic stroke~8. History of acute ischemic stroke in the last 90 days~9. High-risk (massive) acute PE (PE associated with hypotension (systolic BP \< 90 mmHg for \> 15 min).~10. PE associated with syncope and any degree of head trauma~11. PE meeting criteria for intermediate-risk PE and thus for enrollment, but with clinical evidence of deterioration such that the Investigator deems the patient not appropriate for enrollment.~12. Administration of thrombolytic agent within the previous 7 days~13. Pulmonary thrombectomy within the previous 30 days~14. Uncontrolled hypertension defined as systolic blood pressure \>180 mm Hg and/or diastolic blood pressure \>110 mm Hg at randomization~15. Severe ARDS (P/F ratio \< 100)~16. Platelet count lower than 80,000/mm3~17. Known hereditary or acquired hemorrhagic diathesis, coagulation factor deficiency; recent oral anticoagulant therapy with INR \>1.7~18. Arterial puncture at a non-compressible site within the past 5 days~19. Prior brain surgery~20. Severe trauma in the prior 2 weeks~21. Major surgery in the prior 2 weeks~22. Brain malignancy / metastases, brain tumor in past 5 years~23. Brain AVM or ruptured aneurysm at any time~24. Acute myocardial infarction or history of myocardial infarction within the past 3 weeks or cardiac arrest during hospitalization~25. Cardiac tamponade~26. Lumbar puncture with in past 7 days~27. Known abdominal or thoracic aneurysm~28. Acute or chronic renal failure requiring dialysis~29. Chronic liver failure (acutely elevated liver function tests not an exclusion criterion)~30. Bacterial endocarditis at time of study entry~31. Seizure during pre-hospital course or during hospitalization for COVID-19~32. Currently on ECMO~33. Pregnancy, lactation or parturition within the previous 30 days~34. Patients, in whom, in the opinion of the Investigator, are critically ill from concomitant comorbid cardiopulmonary disease, and unlikely to benefit.~35. Any other condition that the Investigator felt would place the patient at increased risk if the investigational therapy were initiated~36. Previous enrollment in this study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Low-dose TNKase and Standard of Care Anticoagulation (Type: EXPERIMENTAL): 1. TNKase (0.25 mg/kg) bolus Other names: Tenecteplase, TNK~2. Standard of care anticoagulation (heparin or enoxaparin)
- Placebo and and Standard of Care Anticoagulation (Type: ACTIVE_COMPARATOR): 1. Placebo bolus (intravenous syringe identical to that of TNK )~2. Standard of care anticoagulation (heparin or enoxaparin)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues